-
1
-
-
84859603846
-
New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper
-
De Caterina R., Husted S., Wallentin L., Andreotti F., Arnesen H., Bachmann F., et al. New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol 2012, 59:1413-1425.
-
(2012)
J Am Coll Cardiol
, vol.59
, pp. 1413-1425
-
-
De Caterina, R.1
Husted, S.2
Wallentin, L.3
Andreotti, F.4
Arnesen, H.5
Bachmann, F.6
-
2
-
-
70349306707
-
Dabigatran versus warfarin in patients with atrial fibrillation
-
Connolly S.J., Ezekowitz M.D., Yusuf S., Eikelboom J., Oldgren J., Parekh A., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-1151.
-
(2009)
N Engl J Med
, vol.361
, pp. 1139-1151
-
-
Connolly, S.J.1
Ezekowitz, M.D.2
Yusuf, S.3
Eikelboom, J.4
Oldgren, J.5
Parekh, A.6
-
3
-
-
80052592404
-
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
-
Patel M.R., Mahaffey K.W., Garg J., Pan G., Singer D.E., Hacke W., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011, 365:883-891.
-
(2011)
N Engl J Med
, vol.365
, pp. 883-891
-
-
Patel, M.R.1
Mahaffey, K.W.2
Garg, J.3
Pan, G.4
Singer, D.E.5
Hacke, W.6
-
4
-
-
80052825103
-
Apixaban versus warfarin in patients with atrial fibrillation
-
Granger C.B., Alexander J.H., McMurray J.J., Lopes R.D., Hylek E.M., Hanna M., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011, 365:981-992.
-
(2011)
N Engl J Med
, vol.365
, pp. 981-992
-
-
Granger, C.B.1
Alexander, J.H.2
McMurray, J.J.3
Lopes, R.D.4
Hylek, E.M.5
Hanna, M.6
-
5
-
-
79952301326
-
Apixaban in patients with atrial fibrillation
-
Connolly S.J., Eikelboom J., Joyner C., Diener H.C., Hart R., Golitsyn S., et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011, 364:806-817.
-
(2011)
N Engl J Med
, vol.364
, pp. 806-817
-
-
Connolly, S.J.1
Eikelboom, J.2
Joyner, C.3
Diener, H.C.4
Hart, R.5
Golitsyn, S.6
-
6
-
-
77957932391
-
Evaluation of the novel Factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the effective anticoagulation with Factor Xa next generation in atrial fibrillation-thrombolysis in myocardial infarction study 48 (ENGAGE AF-TIMI 48)
-
Ruff C.T., Giugliano R.P., Antman E.M., Crugnale S.E., Bocanegra T., Mercuri M., et al. Evaluation of the novel Factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the effective anticoagulation with Factor Xa next generation in atrial fibrillation-thrombolysis in myocardial infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J 2010, 160:635-641.
-
(2010)
Am Heart J
, vol.160
, pp. 635-641
-
-
Ruff, C.T.1
Giugliano, R.P.2
Antman, E.M.3
Crugnale, S.E.4
Bocanegra, T.5
Mercuri, M.6
-
7
-
-
84865807336
-
Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis
-
Harenberg J., Marx S., Diener H.C., Lip G.Y., Marder V.J., Wehling M., et al. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis. Int Angiol 2012, 31:330-339.
-
(2012)
Int Angiol
, vol.31
, pp. 330-339
-
-
Harenberg, J.1
Marx, S.2
Diener, H.C.3
Lip, G.Y.4
Marder, V.J.5
Wehling, M.6
-
8
-
-
78649734571
-
Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate
-
Roskell N.S., Lip G.Y., Noack H., Clemens A., Plumb J.M. Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate. Thromb Haemost 2010, 104:1106-1115.
-
(2010)
Thromb Haemost
, vol.104
, pp. 1106-1115
-
-
Roskell, N.S.1
Lip, G.Y.2
Noack, H.3
Clemens, A.4
Plumb, J.M.5
-
9
-
-
17644409026
-
A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial
-
Eriksson B.I., Dahl O.E., Buller H.R., Hettiarachchi R., Rosencher N., Bravo M.L., et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005, 3:103-111.
-
(2005)
J Thromb Haemost
, vol.3
, pp. 103-111
-
-
Eriksson, B.I.1
Dahl, O.E.2
Buller, H.R.3
Hettiarachchi, R.4
Rosencher, N.5
Bravo, M.L.6
-
10
-
-
33645887346
-
Pharmacokinetics and pharmacodynamics
-
McGraw Hill, L. Brunton (Ed.) The dynamics of drug absorption, distribution, action, and elimination
-
Buxton I. Pharmacokinetics and pharmacodynamics. Goodman & Gilman's The pharmacological basis of therapeutics 2006, 1-39. McGraw Hill. 11 ed. L. Brunton (Ed.).
-
(2006)
Goodman & Gilman's The pharmacological basis of therapeutics
, pp. 1-39
-
-
Buxton, I.1
-
11
-
-
13244266944
-
Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I
-
Eriksson B.I., Dahl O.E., Ahnfelt L., Kalebo P., Stangier J., Nehmiz G., et al. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. J Thromb Haemost 2004, 2:1573-1580.
-
(2004)
J Thromb Haemost
, vol.2
, pp. 1573-1580
-
-
Eriksson, B.I.1
Dahl, O.E.2
Ahnfelt, L.3
Kalebo, P.4
Stangier, J.5
Nehmiz, G.6
-
12
-
-
58149458160
-
Apixaban metabolism and pharmacokinetics after oral administration to humans
-
Raghavan N., Frost C.E., Yu Z., He K., Zhang H., Humphreys W.G., et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 2009, 37:74-81.
-
(2009)
Drug Metab Dispos
, vol.37
, pp. 74-81
-
-
Raghavan, N.1
Frost, C.E.2
Yu, Z.3
He, K.4
Zhang, H.5
Humphreys, W.G.6
-
13
-
-
79960272135
-
Edoxaban: a new oral direct Factor Xa inhibitor
-
Camm A.J., Bounameaux H. Edoxaban: a new oral direct Factor Xa inhibitor. Drugs 2011, 71:1503-1526.
-
(2011)
Drugs
, vol.71
, pp. 1503-1526
-
-
Camm, A.J.1
Bounameaux, H.2
-
14
-
-
77953787643
-
Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel Factor Xa inhibitor edoxaban in healthy volunteers
-
Ogata K., Mendell-Harary J., Tachibana M., Masumoto H., Oguma T., Kojima M., et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel Factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 2010, 50:743-753.
-
(2010)
J Clin Pharmacol
, vol.50
, pp. 743-753
-
-
Ogata, K.1
Mendell-Harary, J.2
Tachibana, M.3
Masumoto, H.4
Oguma, T.5
Kojima, M.6
-
15
-
-
42949123582
-
Population pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct Factor Xa inhibitor - in patients undergoing major orthopaedic surgery
-
Mueck W., Eriksson B.I., Bauer K.A., Borris L., Dahl O.E., Fisher W.D., et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct Factor Xa inhibitor - in patients undergoing major orthopaedic surgery. Clin Pharmacokinet 2008, 47:203-216.
-
(2008)
Clin Pharmacokinet
, vol.47
, pp. 203-216
-
-
Mueck, W.1
Eriksson, B.I.2
Bauer, K.A.3
Borris, L.4
Dahl, O.E.5
Fisher, W.D.6
-
16
-
-
84868523625
-
2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association
-
Camm A.J., Lip G.Y., De Caterina R., Savelieva I., Atar D., Hohnloser S.H., et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012, 33:2719-2747.
-
(2012)
Eur Heart J
, vol.33
, pp. 2719-2747
-
-
Camm, A.J.1
Lip, G.Y.2
De Caterina, R.3
Savelieva, I.4
Atar, D.5
Hohnloser, S.H.6
-
17
-
-
84856158305
-
ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)
-
Hamm C.W., Bassand J.P., Agewall S., Bax J., Boersma E., Bueno H., et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011, 32:2999-3054.
-
(2011)
Eur Heart J
, vol.32
, pp. 2999-3054
-
-
Hamm, C.W.1
Bassand, J.P.2
Agewall, S.3
Bax, J.4
Boersma, E.5
Bueno, H.6
-
18
-
-
84856802635
-
Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines
-
Kearon C., Akl E.A., Comerota A.J., Prandoni P., Bounameaux H., Goldhaber S.Z., et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012, 141:e419S-e494S.
-
(2012)
Chest
, vol.141
-
-
Kearon, C.1
Akl, E.A.2
Comerota, A.J.3
Prandoni, P.4
Bounameaux, H.5
Goldhaber, S.Z.6
-
19
-
-
84856797169
-
Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines
-
Falck-Ytter Y., Francis C.W., Johanson N.A., Curley C., Dahl O.E., Schulman S., et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012, 141:e278S-e325S.
-
(2012)
Chest
, vol.141
-
-
Falck-Ytter, Y.1
Francis, C.W.2
Johanson, N.A.3
Curley, C.4
Dahl, O.E.5
Schulman, S.6
-
20
-
-
35348879239
-
Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO study)
-
Ezekowitz M.D., Reilly P.A., Nehmiz G., Simmers T.A., Nagarakanti R., Parcham-Azad K., et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO study). Am J Cardiol 2007, 100:1419-1426.
-
(2007)
Am J Cardiol
, vol.100
, pp. 1419-1426
-
-
Ezekowitz, M.D.1
Reilly, P.A.2
Nehmiz, G.3
Simmers, T.A.4
Nagarakanti, R.5
Parcham-Azad, K.6
-
21
-
-
35449007749
-
Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial
-
Eriksson B.I., Dahl O.E., Rosencher N., Kurth A.A., van Dijk C.N., Frostick S.P., et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007, 5:2178-2185.
-
(2007)
J Thromb Haemost
, vol.5
, pp. 2178-2185
-
-
Eriksson, B.I.1
Dahl, O.E.2
Rosencher, N.3
Kurth, A.A.4
van Dijk, C.N.5
Frostick, S.P.6
-
22
-
-
34548575058
-
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial
-
Eriksson B.I., Dahl O.E., Rosencher N., Kurth A.A., van Dijk C.N., Frostick S.P., et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007, 370:949-956.
-
(2007)
Lancet
, vol.370
, pp. 949-956
-
-
Eriksson, B.I.1
Dahl, O.E.2
Rosencher, N.3
Kurth, A.A.4
van Dijk, C.N.5
Frostick, S.P.6
-
23
-
-
71849117615
-
Dabigatran versus warfarin in the treatment of acute venous thromboembolism
-
Schulman S., Kearon C., Kakkar A.K., Mismetti P., Schellong S., Eriksson H., et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009, 361:2342-2352.
-
(2009)
N Engl J Med
, vol.361
, pp. 2342-2352
-
-
Schulman, S.1
Kearon, C.2
Kakkar, A.K.3
Mismetti, P.4
Schellong, S.5
Eriksson, H.6
-
24
-
-
80052232522
-
Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial
-
Oldgren J., Budaj A., Granger C.B., Khder Y., Roberts J., Siegbahn A., et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 2011, 32:2781-2789.
-
(2011)
Eur Heart J
, vol.32
, pp. 2781-2789
-
-
Oldgren, J.1
Budaj, A.2
Granger, C.B.3
Khder, Y.4
Roberts, J.5
Siegbahn, A.6
-
25
-
-
33644867218
-
Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement
-
Eriksson B.I., Borris L., Dahl O.E., Haas S., Huisman M.V., Kakkar A.K., et al. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 2006, 4:121-128.
-
(2006)
J Thromb Haemost
, vol.4
, pp. 121-128
-
-
Eriksson, B.I.1
Borris, L.2
Dahl, O.E.3
Haas, S.4
Huisman, M.V.5
Kakkar, A.K.6
-
26
-
-
33751559902
-
A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement
-
Eriksson B.I., Borris L.C., Dahl O.E., Haas S., Huisman M.V., Kakkar A.K., et al. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation 2006, 114:2374-2381.
-
(2006)
Circulation
, vol.114
, pp. 2374-2381
-
-
Eriksson, B.I.1
Borris, L.C.2
Dahl, O.E.3
Haas, S.4
Huisman, M.V.5
Kakkar, A.K.6
-
27
-
-
28444474155
-
BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study
-
Turpie A.G., Fisher W.D., Bauer K.A., Kwong L.M., Irwin M.W., Kalebo P., et al. BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost 2005, 3:2479-2486.
-
(2005)
J Thromb Haemost
, vol.3
, pp. 2479-2486
-
-
Turpie, A.G.1
Fisher, W.D.2
Bauer, K.A.3
Kwong, L.M.4
Irwin, M.W.5
Kalebo, P.6
-
28
-
-
45949099359
-
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty
-
Eriksson B.I., Borris L.C., Friedman R.J., Haas S., Huisman M.V., Kakkar A.K., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008, 358:2765-2775.
-
(2008)
N Engl J Med
, vol.358
, pp. 2765-2775
-
-
Eriksson, B.I.1
Borris, L.C.2
Friedman, R.J.3
Haas, S.4
Huisman, M.V.5
Kakkar, A.K.6
-
29
-
-
46049106502
-
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial
-
Kakkar A.K., Brenner B., Dahl O.E., Eriksson B.I., Mouret P., Muntz J., et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008, 372:31-39.
-
(2008)
Lancet
, vol.372
, pp. 31-39
-
-
Kakkar, A.K.1
Brenner, B.2
Dahl, O.E.3
Eriksson, B.I.4
Mouret, P.5
Muntz, J.6
-
30
-
-
45949103416
-
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty
-
Lassen M.R., Ageno W., Borris L.C., Lieberman J.R., Rosencher N., Bandel T.J., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008, 358:2776-2786.
-
(2008)
N Engl J Med
, vol.358
, pp. 2776-2786
-
-
Lassen, M.R.1
Ageno, W.2
Borris, L.C.3
Lieberman, J.R.4
Rosencher, N.5
Bandel, T.J.6
-
31
-
-
65549169515
-
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial
-
Turpie A.G., Lassen M.R., Davidson B.L., Bauer K.A., Gent M., Kwong L.M., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009, 373:1673-1680.
-
(2009)
Lancet
, vol.373
, pp. 1673-1680
-
-
Turpie, A.G.1
Lassen, M.R.2
Davidson, B.L.3
Bauer, K.A.4
Gent, M.5
Kwong, L.M.6
-
32
-
-
79952496003
-
Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies
-
Turpie A.G., Lassen M.R., Eriksson B.I., Gent M., Berkowitz S.D., Misselwitz F., et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost 2011, 105:444-453.
-
(2011)
Thromb Haemost
, vol.105
, pp. 444-453
-
-
Turpie, A.G.1
Lassen, M.R.2
Eriksson, B.I.3
Gent, M.4
Berkowitz, S.D.5
Misselwitz, F.6
-
33
-
-
25844525489
-
Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct Factor Xa inhibitor
-
Kubitza D., Becka M., Voith B., Zuehlsdorf M., Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct Factor Xa inhibitor. Clin Pharmacol Ther 2005, 78:412-421.
-
(2005)
Clin Pharmacol Ther
, vol.78
, pp. 412-421
-
-
Kubitza, D.1
Becka, M.2
Voith, B.3
Zuehlsdorf, M.4
Wensing, G.5
-
34
-
-
34447317298
-
Treatment of proximal deep-vein thrombosis with the oral direct Factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (oral direct Factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study
-
Agnelli G., Gallus A., Goldhaber S.Z., Haas S., Huisman M.V., Hull R.D., et al. Treatment of proximal deep-vein thrombosis with the oral direct Factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (oral direct Factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation 2007, 116:180-187.
-
(2007)
Circulation
, vol.116
, pp. 180-187
-
-
Agnelli, G.1
Gallus, A.2
Goldhaber, S.Z.3
Haas, S.4
Huisman, M.V.5
Hull, R.D.6
-
35
-
-
53849123533
-
A dose-ranging study evaluating once-daily oral administration of the Factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT dose-ranging study
-
Buller H.R., Lensing A.W., Prins M.H., Agnelli G., Cohen A., Gallus A.S., et al. A dose-ranging study evaluating once-daily oral administration of the Factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT dose-ranging study. Blood 2008, 112:2242-2247.
-
(2008)
Blood
, vol.112
, pp. 2242-2247
-
-
Buller, H.R.1
Lensing, A.W.2
Prins, M.H.3
Agnelli, G.4
Cohen, A.5
Gallus, A.S.6
-
36
-
-
80052485992
-
Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention
-
Mueck W., Lensing A.W., Agnelli G., Decousus H., Prandoni P., Misselwitz F. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 2011, 50:675-686.
-
(2011)
Clin Pharmacokinet
, vol.50
, pp. 675-686
-
-
Mueck, W.1
Lensing, A.W.2
Agnelli, G.3
Decousus, H.4
Prandoni, P.5
Misselwitz, F.6
-
37
-
-
78650619315
-
Oral rivaroxaban for symptomatic venous thromboembolism
-
Bauersachs R., Berkowitz S.D., Brenner B., Buller H.R., Decousus H., Gallus A.S., et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010, 363:2499-2510.
-
(2010)
N Engl J Med
, vol.363
, pp. 2499-2510
-
-
Bauersachs, R.1
Berkowitz, S.D.2
Brenner, B.3
Buller, H.R.4
Decousus, H.5
Gallus, A.S.6
-
38
-
-
84859385808
-
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism
-
Buller H.R., Prins M.H., Lensin A.W., Decousus H., Jacobson B.F., Minar E., et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012, 366:1287-1297.
-
(2012)
N Engl J Med
, vol.366
, pp. 1287-1297
-
-
Buller, H.R.1
Prins, M.H.2
Lensin, A.W.3
Decousus, H.4
Jacobson, B.F.5
Minar, E.6
-
39
-
-
84861229431
-
New anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation
-
Tripodi A., Palareti G. New anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation. J Intern Med 2012, 271:554-565.
-
(2012)
J Intern Med
, vol.271
, pp. 554-565
-
-
Tripodi, A.1
Palareti, G.2
-
40
-
-
67649562905
-
Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial
-
Mega J.L., Braunwald E., Mohanavelu S., Burton P., Poulter R., Misselwitz F., et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009, 374:29-38.
-
(2009)
Lancet
, vol.374
, pp. 29-38
-
-
Mega, J.L.1
Braunwald, E.2
Mohanavelu, S.3
Burton, P.4
Poulter, R.5
Misselwitz, F.6
-
41
-
-
84862907587
-
Rivaroxaban in patients with a recent acute coronary syndrome
-
Mega J.L., Braunwald E., Wiviott S.D., Bassand J.P., Bhatt D.L., Bode C., et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012, 366:9-19.
-
(2012)
N Engl J Med
, vol.366
, pp. 9-19
-
-
Mega, J.L.1
Braunwald, E.2
Wiviott, S.D.3
Bassand, J.P.4
Bhatt, D.L.5
Bode, C.6
-
42
-
-
36348978071
-
The efficacy and safety of apixaban, an oral, direct Factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement
-
Lassen M.R., Davidson B.L., Gallus A., Pineo G., Ansell J., Deitchman D. The efficacy and safety of apixaban, an oral, direct Factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 2007, 5:2368-2375.
-
(2007)
J Thromb Haemost
, vol.5
, pp. 2368-2375
-
-
Lassen, M.R.1
Davidson, B.L.2
Gallus, A.3
Pineo, G.4
Ansell, J.5
Deitchman, D.6
-
43
-
-
77649249878
-
Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale
-
Lopes R.D., Alexander J.H., Al-Khatib S.M., Ansell J., Diaz R., Easton J.D., et al. Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J 2010, 159:331-339.
-
(2010)
Am Heart J
, vol.159
, pp. 331-339
-
-
Lopes, R.D.1
Alexander, J.H.2
Al-Khatib, S.M.3
Ansell, J.4
Diaz, R.5
Easton, J.D.6
-
44
-
-
78650587760
-
Apixaban versus enoxaparin for thromboprophylaxis after hip replacement
-
Lassen M.R., Gallus A., Raskob G.E., Pineo G., Chen D., Ramirez L.M. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010, 363:2487-2498.
-
(2010)
N Engl J Med
, vol.363
, pp. 2487-2498
-
-
Lassen, M.R.1
Gallus, A.2
Raskob, G.E.3
Pineo, G.4
Chen, D.5
Ramirez, L.M.6
-
45
-
-
77649113258
-
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial
-
Lassen M.R., Raskob G.E., Gallus A., Pineo G., Chen D., Hornick P. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010, 375:807-815.
-
(2010)
Lancet
, vol.375
, pp. 807-815
-
-
Lassen, M.R.1
Raskob, G.E.2
Gallus, A.3
Pineo, G.4
Chen, D.5
Hornick, P.6
-
46
-
-
67649563209
-
Apixaban, an oral, direct, selective Factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the apixaban for prevention of acute ischemic and safety events (APPRAISE) trial
-
Alexander J.H., Becker R.C., Bhatt D.L., Cools F., Crea F., Dellborg M., et al. Apixaban, an oral, direct, selective Factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the apixaban for prevention of acute ischemic and safety events (APPRAISE) trial. Circulation 2009, 119:2877-2885.
-
(2009)
Circulation
, vol.119
, pp. 2877-2885
-
-
Alexander, J.H.1
Becker, R.C.2
Bhatt, D.L.3
Cools, F.4
Crea, F.5
Dellborg, M.6
-
47
-
-
80052162121
-
Apixaban with antiplatelet therapy after acute coronary syndrome
-
Alexander J.H., Lopes R.D., James S., Kilaru R., He Y., Mohan P., et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011, 365:699-708.
-
(2011)
N Engl J Med
, vol.365
, pp. 699-708
-
-
Alexander, J.H.1
Lopes, R.D.2
James, S.3
Kilaru, R.4
He, Y.5
Mohan, P.6
-
48
-
-
0034871011
-
A systematic review of the associations between dose regimens and medication compliance
-
Claxton A.J., Cramer J., Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001, 23:1296-1310.
-
(2001)
Clin Ther
, vol.23
, pp. 1296-1310
-
-
Claxton, A.J.1
Cramer, J.2
Pierce, C.3
-
49
-
-
84866480694
-
Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients
-
Laliberte F., Nelson W.W., Lefebvre P., Schein J.R., Rondeau-Leclaire J., Duh M.S. Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients. Adv Ther 2012, 29:675-690.
-
(2012)
Adv Ther
, vol.29
, pp. 675-690
-
-
Laliberte, F.1
Nelson, W.W.2
Lefebvre, P.3
Schein, J.R.4
Rondeau-Leclaire, J.5
Duh, M.S.6
-
50
-
-
84861220176
-
Effect of dosing frequency on chronic cardiovascular disease medication adherence
-
Coleman C.I., Roberts M.S., Sobieraj D.M., Lee S., Alam T., Kaur R. Effect of dosing frequency on chronic cardiovascular disease medication adherence. Curr Med Res Opin 2012, 28:669-680.
-
(2012)
Curr Med Res Opin
, vol.28
, pp. 669-680
-
-
Coleman, C.I.1
Roberts, M.S.2
Sobieraj, D.M.3
Lee, S.4
Alam, T.5
Kaur, R.6
-
51
-
-
77954361232
-
Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral Factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation
-
Weitz J.I., Connolly S.J., Patel I., Salazar D., Rohatagi S., Mendell J., et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral Factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost 2010, 104:633-641.
-
(2010)
Thromb Haemost
, vol.104
, pp. 633-641
-
-
Weitz, J.I.1
Connolly, S.J.2
Patel, I.3
Salazar, D.4
Rohatagi, S.5
Mendell, J.6
-
52
-
-
78149236861
-
A dose-ranging study evaluating the oral Factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty
-
Fuji T., Fujita S., Tachibana S., Kawai Y. A dose-ranging study evaluating the oral Factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty. J Thromb Haemost 2010, 8:2458-2468.
-
(2010)
J Thromb Haemost
, vol.8
, pp. 2458-2468
-
-
Fuji, T.1
Fujita, S.2
Tachibana, S.3
Kawai, Y.4
-
53
-
-
82555178116
-
Safety and efficacy of edoxaban in patients undergoing hip fracture surgery (abstract)
-
Fujita S., Fuji T., Tachibana S., Nakamura M., Kawai Y. Safety and efficacy of edoxaban in patients undergoing hip fracture surgery (abstract). Pathophysiol Haemost Thromb 2010, 37:P366.
-
(2010)
Pathophysiol Haemost Thromb
, vol.37
-
-
Fujita, S.1
Fuji, T.2
Tachibana, S.3
Nakamura, M.4
Kawai, Y.5
-
54
-
-
84880397241
-
Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study - methodological implications for clinical trials
-
Raskob G., Buller H., Prins M., Segers A., Shi M., Schwocho L., et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study - methodological implications for clinical trials. J Thromb Haemost 2013, 11:1287-1294.
-
(2013)
J Thromb Haemost
, vol.11
, pp. 1287-1294
-
-
Raskob, G.1
Buller, H.2
Prins, M.3
Segers, A.4
Shi, M.5
Schwocho, L.6
-
55
-
-
34447639584
-
A dose escalation study of YM150, an oral direct Factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery
-
Eriksson B.I., Turpie A.G., Lassen M.R., Prins M.H., Agnelli G., Kalebo P., et al. A dose escalation study of YM150, an oral direct Factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery. J Thromb Haemost 2007, 5:1660-1665.
-
(2007)
J Thromb Haemost
, vol.5
, pp. 1660-1665
-
-
Eriksson, B.I.1
Turpie, A.G.2
Lassen, M.R.3
Prins, M.H.4
Agnelli, G.5
Kalebo, P.6
-
56
-
-
77649141852
-
Prevention of venous thromboembolism with an oral Factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2)
-
Eriksson B.I., Turpie A.G., Lassen M.R., Prins M.H., Agnelli G., Kalebo P., et al. Prevention of venous thromboembolism with an oral Factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2). J Thromb Haemost 2010, 8:714-721.
-
(2010)
J Thromb Haemost
, vol.8
, pp. 714-721
-
-
Eriksson, B.I.1
Turpie, A.G.2
Lassen, M.R.3
Prins, M.H.4
Agnelli, G.5
Kalebo, P.6
-
57
-
-
80054742836
-
Safety and tolerability of the oral Factor Xa inhibitor, YM150 versus warfarin in 1297 patients with non-valvular atrial fibrillation: a dose confirmation study (OPAL-2)
-
[abstract]
-
Lip G., Halperin J., Petersen P., Rodgers G., Renfurm R. Safety and tolerability of the oral Factor Xa inhibitor, YM150 versus warfarin in 1297 patients with non-valvular atrial fibrillation: a dose confirmation study (OPAL-2). J Thromb Haemost 2011, 9(Suppl. 2):748. [abstract].
-
(2011)
J Thromb Haemost
, vol.9
, Issue.SUPPL. 2
, pp. 748
-
-
Lip, G.1
Halperin, J.2
Petersen, P.3
Rodgers, G.4
Renfurm, R.5
-
58
-
-
80054733922
-
RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral Factor Xa inhibitor darexaban (YM150) following acute coronary syndrome
-
Steg P.G., Mehta S.R., Jukema J.W., Lip G.Y., Gibson C.M., Kovar F., et al. RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral Factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J 2011, 32:2541-2554.
-
(2011)
Eur Heart J
, vol.32
, pp. 2541-2554
-
-
Steg, P.G.1
Mehta, S.R.2
Jukema, J.W.3
Lip, G.Y.4
Gibson, C.M.5
Kovar, F.6
-
59
-
-
77955926663
-
Quantification of apixaban's therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose
-
Leil T.A., Feng Y., Zhang L., Paccaly A., Mohan P., Pfister M. Quantification of apixaban's therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose. Clin Pharmacol Ther 2010, 88:375-382.
-
(2010)
Clin Pharmacol Ther
, vol.88
, pp. 375-382
-
-
Leil, T.A.1
Feng, Y.2
Zhang, L.3
Paccaly, A.4
Mohan, P.5
Pfister, M.6
-
60
-
-
84860526602
-
Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation
-
Salazar D.E., Mendell J., Kastrissios H., Green M., Carrothers T.J., Song S., et al. Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation. Thromb Haemost 2012, 107:925-936.
-
(2012)
Thromb Haemost
, vol.107
, pp. 925-936
-
-
Salazar, D.E.1
Mendell, J.2
Kastrissios, H.3
Green, M.4
Carrothers, T.J.5
Song, S.6
|